Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Primary Peptides

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PP-002

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-002

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Qingdao Primedicine Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 19, 2020

            Details:

            Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PP-001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-001

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Simcere Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 11, 2020

            Details:

            Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): K13

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Yabao Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 15, 2015

            Details:

            Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.